이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

공황 장애에 대한 HB-1의 효능 및 안전성: 다기관, 무작위, 이중 맹검, 위약 대조 시험

2026년 9월 21일 업데이트: HB BioTech, LLC

The purpose of this study is to determine the safety and efficacy of HB-1, versus placebo and two monotherapies, in male and female adult patients aged 18 to 65 years, inclusive, with Panic Disorder.

연구 개요

상태

종료됨

정황

개입 / 치료

상세 설명

This is a multicenter, randomized, double-blind, placebo-controlled trial. All patients with Panic Disorder, with or without specified co-morbidities, who meet all of the inclusion and none of the exclusion criteria will be eligible. Patients and researchers will be blinded to their treatment group.

The study will enroll approximately 240 (up to 600) adult patients who meet the diagnosis of panic disorder.

Patients will be treated for 12 weeks followed by a safety follow up visit one week after their last dose of study treatment.

연구 유형

중재적

등록 (실제)

170

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • Australian Capital Territory
      • Canberra, Australian Capital Territory, 호주, 2617
        • Paratus Clinical Research Canberra
    • New South Wales
      • Blacktown, New South Wales, 호주, 2148
        • Paratus Clinical Research Western Sydney
      • Charlestown, New South Wales, 호주, 2290
        • Novatrials
      • Darlinghurst, New South Wales, 호주, 2010
        • East Sydney Doctors
      • Darlinghurst, New South Wales, 호주, 2010
        • Momentum Clinical Research Darlinghurst
      • Miranda, New South Wales, 호주, 2228
        • Canopy Clinical Sutherland
      • Waitara, New South Wales, 호주, 2077
        • Innovate Clinical Research
      • Westmead, New South Wales, 호주, 2145
        • Westmead Hospital
      • Wollongong, New South Wales, 호주, 2500
        • Canopy Clinical Wollongong
    • Queensland
      • Herston, Queensland, 호주, 4006
        • Paratus Clinical Research Brisbane
      • Mackay, Queensland, 호주, 4740
        • Mackay Hospital and Health Service
    • South Australia
      • Adelaide, South Australia, 호주, 5000
        • South Australian Health and Medical Research Institute
    • Victoria
      • Carlton, Victoria, 호주, 3053
        • NeuroCentrix
      • Frankston, Victoria, 호주, 3199
        • Peninsula Therapeutic and Research Group
      • Melbourne, Victoria, 호주, 3004
        • Ramsay Clinic Albert Road
      • Melbourne, Victoria, 호주, 3004
        • Multidisciplinary Alfred Psychiatry Research Clinic
      • Northcote, Victoria, 호주, 3070
        • Paratus Clinical Research Melbourne
      • Torquay, Victoria, 호주, 3228
        • Clinical Trials Institute
    • Western Australia
      • West Perth, Western Australia, 호주, 6005
        • Clinitrials

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  1. Male or female aged 18 to 65 years old, inclusive, at the time of informed consent.
  2. Meets Diagnostic and Statistical Manual of Mental Disorders 5th Edition (DSM-V) Criteria for Panic Disorder.
  3. Minimum of one full, unexpected panic attack in week prior to screening (via Diagnostic and Statistical Manual of Mental Disorders 5th edition [DSM-V] based structured interview).
  4. Medically stable on current medication regimen for at least 3 months (including as needed [PRN] medications), as determined by Investigator.
  5. Willing to remain on current doses of other psychiatric medications throughout the length of the trial.
  6. Willing and able to safely stop / avoid any of the following prior to study trial: Inhibitors or inducers of CYP3A4 (grapefruit juice, erythromycin, ritonavir, telithromycin, rifampin), HMG-CoA Reductase Inhibitors (Simvastatin, Lovastatin, Atorvastatin), Beta Blockers (Timolol eyedrops, Metoprolol), Neuromuscular Blocking Agents (curare-like and depolarizing), Antihypertensive Agents (Prazosin and vasodilators, angiotensin-converting enzyme inhibitors, diuretics, beta blockers), Inhalation Anesthetics, Disopyramide, Flecainide, Quinidine, Cimetidine, Lithium, Carbamazepine, Phenobarbital, Cyclosporine, Digitalis, Aliskiren, Ramipril and Ramiprilat, aspirin, propranolol.
  7. Willing and able to safely stop / avoid sensitive P-glycoprotein inhibitors.
  8. Willing to take HB-1, telmisartan, verapamil, or placebo.
  9. Willing and able to provide informed consent indicating an understanding of the requirements of the study and a willingness to comply with scheduled visits and all study procedures.
  10. Female subjects must be surgically sterile (or have a monogamous partner who is surgically sterile) or be at least 2 years postmenopausal or commit to use 2 acceptable forms of birth control (defined as the use of an intrauterine device, a barrier method with spermicide, condoms, any form of hormonal contraceptives, or abstinence) for the duration of the study and for 4 months following the last dose of study treatment. Male subjects must be sterile (biologically or surgically) or commit to the use of a reliable method of birth control (condoms ± spermicide) for the duration of the study and for 4 months following the last dose of study treatment. Individuals who are involved exclusively in same-sex relationships are exempt from the birth control requirements but must agree to abide by the recommendations if they do engage in a heterosexual relationship.
  11. Female subjects who are women of childbearing potential (WOCBP) must have a negative pregnancy test at Screening, within 7 days of dosing with study treatment.

Exclusion Criteria:

  1. Any concomitant disease, condition, or treatment that could interfere with the conduct of the study, or that would, in the opinion of the Investigator or Sponsor, pose an unacceptable risk to the participant in the study or interfere with the interpretation of study data.
  2. Concurrent treatment with benzodiazepines (e.g. alprazolam, diazepam, clonazepam, lorazepam) as assessed by clinical interview and urine toxicology testing.
  3. Severe Agoraphobia (Panic Disorder Symptom Severity Scale (PDSS) Item 4 "agoraphobic fear/avoidance" > 2).
  4. Severe Generalized Anxiety (Hamilton Anxiety Rating Scale [HAM-A] Total Score > 23).
  5. Prior lifetime history of suicide attempt, Columbia Suicide Severity Rating Scale (C-SSRS) ≥ 4 in the past 6 months or prior lifetime history of hospitalization for depression.
  6. Diagnosis of Substance Use Disorder, Obsessive-Compulsive Disorder (OCD), Bipolar I, Bipolar II disorder or schizoaffective or other psychotic disorders (per Structure Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders 5th Edition (DSM-V) [SCID-V].
  7. Severe uncontrolled cardiac disease within 6 months of Screening, including but not limited to uncontrolled hypertension, hypotension (defined as below 90/60); unstable angina; myocardial infarction (MI) or cerebrovascular accident (CVA).
  8. Any clinically significant electrocardiogram (ECG) abnormalities at screening.
  9. Inadequate hepatic function defined as total bilirubin > 1.5 × the upper limit of normal (ULN) ranges of each institution, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) > 3 × the ULN range of each institution.
  10. Inadequate renal function defined as serum creatinine > 1.5 × the upper limit of normal (ULN) range of each institution and/or estimated glomerular filtration rate (eGFR) < 60.
  11. Any clinically significant abnormalities in clinical laboratory assessments as assessed by the Investigator.
  12. Any other systemic conditions or organ abnormalities that in the opinion of the Investigator may interfere with the conduct and/or interpretation of the current study.
  13. Unable to complete neuropsychological testing.
  14. Already on treatment with either telmisartan or verapamil or both.
  15. Has a history of hypersensitivity or severe allergic reaction to either telmisartan or verapamil, or any component of either licensed drug.
  16. Documented contraindication to taking telmisartan or verapamil: (e.g., Duchenne's muscular dystrophy, myasthenia gravis).
  17. Pregnant or breastfeeding.
  18. Participation in another current clinical trial or prior trial within the last three months.
  19. Urinalysis evidence of exposure to substances that may interfere with HB-1 testing (per investigator discretion).

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 삼루타

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: HB-1

HB-1 fixed dose, once daily.

HB-1 will be supplied as a dual active pharmaceutical ingredient tablet.

다른 이름들:
  • 고정 용량 Telmisartan / Verapamil 정제
실험적: Telmisartan

Telmisartan fixed dose, once daily.

Telmisartan will be supplied as a single active pharmaceutical ingredient tablet.

다른 이름들:
  • 텔미사르탄
실험적: Verapamil

Verapamil fixed dose, once daily.

Verapamil will be supplied as a single active pharmaceutical ingredient tablet.

다른 이름들:
  • 베라파밀
위약 비교기: Placebo

Placebo treatment, once daily

Matched Placebo will be supplied as a tablet.

다른 이름들:
  • 일치하는 위약

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Number of Unexpected Panic Attacks
기간: Screening, Week 3, Week 4, Week 5, Week 6, Week 7, Week 8, Week 9, Week 10, Week 11, and Week 12

Efficacy will be evaluated through a comparison of the number of unexpected panic attack days (over the last 10 weeks in a 12-week treatment period) from Screening as compared to protocol-specified timepoints per protocol.

Screening, Week 3, Week 4, Week 5, Week 6, Week 7, Week 8, Week 9, Week 10, Week 11, and Week 12
Incidence of Treatment-Emergent Adverse Events
기간: Baseline, Week 2, Week 4, Week 6, Week 8, Week 10, Week 12 and Week 13.

Safety will be evaluated through the monitoring of Adverse Events and the review of clinically significant changes in routine laboratory tests, ECGs, and orthostatic vital signs.

Baseline, Week 2, Week 4, Week 6, Week 8, Week 10, Week 12 and Week 13.

2차 결과 측정

결과 측정
측정값 설명
기간
Change in Clinical Global Impression-Severity Scale (CGI-S)
기간: Baseline, Week 4, Week 8 and Week 12

Efficacy will be evaluated through an evaluation in Clinical Global Impression Severity scale (CGI-S) scores from Baseline as compared to protocol-specified timepoints per protocol. The Clinical Global Impression Severity Scale is rated on a 7-point scale, with the severity of illness scale using a range of responses from 1 (normal) through to 7 (amongst the most severely ill patients).

Baseline, Week 4, Week 8 and Week 12
Change in Panic Disorder Symptom Severity Scale (PDSS)
기간: Screening, Week 4, Week 8 and Week 12

Efficacy will be evaluated through an evaluation in Panic Disorder Symptom Severity Scale (PDSS) scores from Screening as compared to protocol-specified timepoints per protocol.

Screening, Week 4, Week 8 and Week 12

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 수석 연구원: Prof. Malcolm Hopwood, Ramsay Clinic Albert Road

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2024년 10월 29일

기본 완료 (실제)

2026년 9월 9일

연구 완료 (실제)

2026년 9월 9일

연구 등록 날짜

최초 제출

2024년 6월 26일

QC 기준을 충족하는 최초 제출

2024년 6월 26일

처음 게시됨 (실제)

2024년 7월 3일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 24일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 21일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • HB-PD-002

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

미국에서 제조되어 미국에서 수출되는 제품

예

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .